A Phase I First-In-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients With Advanced Solid Tumors

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-15-1221

Related search